506 related articles for article (PubMed ID: 21497176)
1. Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology.
Milane L; Ganesh S; Shah S; Duan ZF; Amiji M
J Control Release; 2011 Oct; 155(2):237-47. PubMed ID: 21497176
[TBL] [Abstract][Full Text] [Related]
2. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
3. Nanocarriers in Improving Chemotherapy of Multidrug Resistant Tumors: Key Developments and Perspectives.
Chistiakov DA; Myasoedova VA; Orekhov AN; Bobryshev YV
Curr Pharm Des; 2017; 23(22):3301-3308. PubMed ID: 28403792
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic potential of targeting ABC transporters to combat multi-drug resistance.
Bugde P; Biswas R; Merien F; Lu J; Liu DX; Chen M; Zhou S; Li Y
Expert Opin Ther Targets; 2017 May; 21(5):511-530. PubMed ID: 28335655
[TBL] [Abstract][Full Text] [Related]
5. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
6. Multifunctional approaches utilizing polymeric micelles to circumvent multidrug resistant tumors.
Kesharwani SS; Kaur S; Tummala H; Sangamwar AT
Colloids Surf B Biointerfaces; 2019 Jan; 173():581-590. PubMed ID: 30352379
[TBL] [Abstract][Full Text] [Related]
7. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
8. Overcoming multidrug resistance in cancer: Recent progress in nanotechnology and new horizons.
Majidinia M; Mirza-Aghazadeh-Attari M; Rahimi M; Mihanfar A; Karimian A; Safa A; Yousefi B
IUBMB Life; 2020 May; 72(5):855-871. PubMed ID: 31913572
[TBL] [Abstract][Full Text] [Related]
9. Revisiting the ABCs of multidrug resistance in cancer chemotherapy.
Tiwari AK; Sodani K; Dai CL; Ashby CR; Chen ZS
Curr Pharm Biotechnol; 2011 Apr; 12(4):570-94. PubMed ID: 21118094
[TBL] [Abstract][Full Text] [Related]
10. Nanopreparations to overcome multidrug resistance in cancer.
Patel NR; Pattni BS; Abouzeid AH; Torchilin VP
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1748-62. PubMed ID: 23973912
[TBL] [Abstract][Full Text] [Related]
11. Multifunctional nanoplatforms co-delivering combinatorial dual-drug for eliminating cancer multidrug resistance.
Wei X; Song M; Li W; Huang J; Yang G; Wang Y
Theranostics; 2021; 11(13):6334-6354. PubMed ID: 33995661
[TBL] [Abstract][Full Text] [Related]
12. Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer.
Yadav P; Ambudkar SV; Rajendra Prasad N
J Nanobiotechnology; 2022 Sep; 20(1):423. PubMed ID: 36153528
[TBL] [Abstract][Full Text] [Related]
13. Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR.
Mohammad IS; He W; Yin L
Biomed Pharmacother; 2018 Apr; 100():335-348. PubMed ID: 29453043
[TBL] [Abstract][Full Text] [Related]
14. Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology.
Xue X; Liang XJ
Chin J Cancer; 2012 Feb; 31(2):100-9. PubMed ID: 22237039
[TBL] [Abstract][Full Text] [Related]
15. Tackling multidrug resistance mediated by efflux transporters in tumor-initiating cells.
McIntosh K; Balch C; Tiwari AK
Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):633-44. PubMed ID: 27116192
[TBL] [Abstract][Full Text] [Related]
16. Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities.
Kirtane AR; Kalscheuer SM; Panyam J
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1731-47. PubMed ID: 24036273
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial targeted doxorubicin derivatives delivered by ROS-responsive nanocarriers to breast tumor for overcoming of multidrug resistance.
Zhong XC; Shi MH; Liu HN; Chen JJ; Wang TT; Lin MT; Zhang ZT; Zhou Y; Lu YY; Xu WH; Gao JQ; Xu DH; Han M; Chen YD
Pharm Dev Technol; 2021 Jan; 26(1):21-29. PubMed ID: 33070673
[TBL] [Abstract][Full Text] [Related]
18. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
[TBL] [Abstract][Full Text] [Related]
19. Nanocarriers overcoming biological barriers induced by multidrug resistance of chemotherapeutics in 2D and 3D cancer models.
Petrikaite V; D'Avanzo N; Celia C; Fresta M
Drug Resist Updat; 2023 May; 68():100956. PubMed ID: 36958083
[TBL] [Abstract][Full Text] [Related]
20. Co-delivery strategies to overcome multidrug resistance in ovarian cancer.
Khan IU; Khan RU; Asif H; Alamgeer ; Khalid SH; Asghar S; Saleem M; Shah KU; Shah SU; Rizvi SAA; Shahzad Y
Int J Pharm; 2017 Nov; 533(1):111-124. PubMed ID: 28947245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
